Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.51
-0.1400-8.48%
Pre-market: 1.570.0600+3.97%04:01 EDT
Volume:3.36M
Turnover:5.22M
Market Cap:639.76M
PE:-10.89
High:1.66
Open:1.65
Low:1.49
Close:1.65
52wk High:1.83
52wk Low:0.3600
Shares:423.68M
Float Shares:418.00M
Volume Ratio:1.33
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1387
EPS(LYR):-0.1387
ROE:-39.72%
ROA:-12.65%
PB:5.95
PE(LYR):-10.89

Loading ...

Lexicon announces common stock offering, no amount given

TIPRANKS
·
Jan 30

Lexicon Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jan 30

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

GlobeNewswire
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug

Reuters
·
Jan 21

Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain

Reuters
·
Jan 21

Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target

TIPRANKS
·
Jan 21

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)

TIPRANKS
·
Jan 16

Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference

Reuters
·
Jan 12

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments

Reuters
·
Jan 09

Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk

Reuters
·
Dec 10, 2025

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

GlobeNewswire
·
Dec 10, 2025

Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients

Reuters
·
Dec 05, 2025

Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences

Reuters
·
Nov 25, 2025

Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing

Reuters
·
Nov 20, 2025

Lexicon Pharmaceuticals Q3 EPS USD -0.04

Reuters
·
Nov 20, 2025